



## Recent USP Updates

May, 2013

Don Singer  
GSK

---

---

---

---

---




---

---

---

### Bioburden Control of Non-sterile Drug Substances and Products <1115>

- The chapter emphasizes control as a risk mitigation strategy
- The chapter recommends a risk-based approach to bioburden control in non-sterile drug products

---

---

---

---

---

---

---

---

### Content of <1115>

<ul style="list-style-type: none"> <li>• Introduction</li> <li>• Guidance Documents</li> <li>• Microbial Control Considerations in Product Development</li> <li>• Microbial Control Considerations in Routine Manufacturing</li> <li>• Water Systems and Usage</li> <li>• Role of Active Pharmaceutical Ingredients, In-process Materials and Excipients</li> </ul>	<ul style="list-style-type: none"> <li>• Equipment Design and Use Considerations</li> <li>• Personnel</li> <li>• The Manufacturing Environment</li> <li>• Microbial Assessment of Non-sterile Product Manufacturing Environments</li> <li>• Microbial Sampling</li> <li>• Microbial Control of Drug Substance Manufacturing</li> <li>• Overall Management of a Microbiological Control Program</li> </ul>
---	---

---

---

---

---

---

---

---

---

### <1115> approach



- A scientific approach to the management of the microbial bioburden in non-sterile products requires consideration of patient risk and control objectives.
- A risk-based approach to control potential contamination in non sterile product manufacturing.

It is important to understand that the manufacture and management of microbiological content of non-sterile products is distinctly different from that required for sterile products.

---

---

---

---

---

---

---

---

### Microbiological Influences




---

---

---

---

---

---

---

---

### What to learn from <1115>



- A microbiological contamination control program should be developed with identifying and controlling product risk based upon a formal assessment of risk modalities.
- The risk analysis activity should result in the establishment of critical control points and should facilitate proper equipment selection, process and facility design requirements.
- To be published in July –August 2013 issue of Pharmacopeial Forum.

---

---

---

---

---

---

---

---

### <1116> Microbiological Control and Monitoring of Aseptic Processing

USP 35 NF 30 (2012)

- ISO-14644 standards are referenced for clean rooms
- **New paradigm for monitoring control of clean rooms based on trending contamination rates**
- Discussion about uncertainty of microbial recovery in ultra clean environments




---

---

---

---

---

---

---

---

### Overview of <1116>



- Contamination rates suggested instead of alert and action levels for manned and unmanned environments.
- Suggestion for investigation in the event of a significant excursion, which is defined as >15CFU for surface, personnel, or active air sampling.
- Discussion on analytical measurement and result interpretation.
- Intended to be applied only for environments in which aseptic processing is performed / supported;
- Drops all reference to EU Grades; all clean room classification is based upon ISO 14644.

---

---

---

---

---

---

---

---

### Contamination Rate Table 3

Grade	Active air sample	Settle Plate (9cm) 4hr exposure	Contact Plate or Swab	Glove or Garment
Isolator or Closed RABS (ISO 5 or better)	<0.1%	<0.1%	<0.1%	<0.1%
ISO 5	<1%	<1%	<1%	<1%
ISO 6	<3%	<3%	<3%	<3%
ISO 7	<5%	<5%	<5%	<5%
ISO 8	<10%	<10%	<10%	<10%

---

---

---

---

---

---

---

---

### Classifications and Applicability in



<1116>



- A comment made by several stakeholders on the final revision of <1116> was that they could not meet the incidence rate expectations for some ISO 7 and ISO 8 rooms.
- This question raises a general issue regarding attempts to apply similar or identical requirements to rooms of the same classification but differing contamination control intention.
- Not all rooms of the same ISO classification can be expected to perform at the same level of microbiological contamination control.

---

---

---

---

---

---

---

---

### Aseptic Processing and <1116>



- We developed <1116> with the intention that it applied only to classified clean space in which full aseptic gowning was required.
- ISO 7 or 8 environments that do not require full aseptic gowning will in most cases not meet the contamination rates recommended in <1116>.
- <1116> will not apply to many preparation rooms, sterilizer rooms, corridors, or even changing rooms prior to the donning of the full aseptic gown.
- Users should develop their own rate criteria for their controlled and classified environments that do not require complete aseptic gowning.

---

---

---

---

---

---

---

---

### Summary of <1116>



- We believe that the contamination rates in <1116> are routinely attainable in aseptic environments where typical full gowning is required.
- Microbiological classification of environments is not a value added activity.
- It is analytically wrong to treat minor differences such as 1CFU compared to 3 or 4CFU to be significant from a process control perspective.
- EM should be treated as a general hygienic survey rather than a measure of sterility assurance.

---

---

---

---

---

---

---

---

Why the designation of 15CFU as a significant excursion?

- Assessment of environmental contamination is not a precise science, it is not at all clear that a finding of 8CFU is clearly more significant than one of 2CFU or 3CFU.
- 15CFU is a result that is more likely to be the result of a significant excursion rather than the result of a sampling artifact.
- If a finding of 15CFU or more turns out to be an isolated finding and does not correlate with short term increase in contamination rate it may not warrant any corrective action.



---

---

---

---

---

---

---

---



Two General Information chapters

- Aseptic Process
- Bioburden Control of Non-sterile

A pragmatic approach to educate

---

---

---

---

---

---

---

---